Investigational drug · Phase 2
NNC0519-0130
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Chronic Kidney Disease, Diabetes Mellitus, Type 2, Obesity.
Phase 2Last checked: Nov 20, 2026Latest source record: Sep 21, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
3
1 still active
All registered trials
11
Any phase or sponsor naming "NNC0519-0130"
First trial start
2024
Mar 18, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "NNC0519-0130", any sponsor or status.
Conditions studied
As listed on its trial records.
- Chronic Kidney Disease
- Diabetes Mellitus, Type 2
- Obesity
Approved drugs for the same conditions: Obesity and weight management · Chronic kidney disease · Cardiovascular and metabolic · Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "NNC0519-0130" as an intervention, largest first.
- A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney DiseasePivotal-lookingRecruiting
Novo Nordisk A/SNovo Nordisk (NVO)
NCT06717698 · 465 participants (planned) · Start Dec 2, 2024 · Primary completion Sep 1, 2026
Drug: NNC0519-0130; Placebo and 1 more · For: Chronic Kidney Disease
Sites: San Dimas, California; San Ramon, California; Aurora, Colorado · 147 sites in all
- A Research Study Comparing How Well Different Doses of the Medicine NN0519-0130 Help People With Excess Body Weight Lose WeightPivotal-lookingCompleted
Novo Nordisk A/SNovo Nordisk (NVO)
NCT06326060 · 354 participants · Start Mar 18, 2024 · Primary completion Apr 10, 2025
Drug: NNC0519-0130; Placebo and 1 more · For: Obesity
Sites: Mesa, Arizona; Little Rock, Arkansas; Searcy, Arkansas · 70 sites in all
- A Research Study Comparing How Well Different Doses of the Medicine NN0519-0130 Lower Blood Sugar in People With Type 2 DiabetesPivotal-lookingCompleted
Novo Nordisk A/SNovo Nordisk (NVO)
NCT06326047 · 299 participants · Start Mar 18, 2024 · Primary completion Sep 19, 2025
Drug: NNC0519-0130; Placebo and 1 more · For: Diabetes Mellitus, Type 2
Sites: Chula Vista, California; Fresno, California; Inglewood, California · 110 sites in all
- A Research Study of a New Medicine NNC0519-0130 in Healthy People, People With High Body Weight and People With Type 2 Diabetes.Pivotal-lookingCompleted
Novo Nordisk A/SNovo Nordisk (NVO)
NCT05363774 · 161 participants · Start Apr 20, 2022 · Primary completion Apr 2, 2024
Drug: NNC0519-0130; Placebo (NNC0519-0130) · For: Healthy Volunteers (Diabetes Mellitus, Type 2)
Sites: Søborg, Denmark; Mainz, Germany; Neuss, Germany
- A Research Study Comparing Different Ways of Increasing the Dose of NNC0519-0130 in Participants With Overweight or ObesityPivotal-lookingCompleted
Novo Nordisk A/SNovo Nordisk (NVO)
NCT06718998 · 134 participants · Start Nov 20, 2024 · Primary completion Jan 12, 2026
Drug: NNC0519-0130 · For: Obesity
Sites: Graz, Austria
Novo Nordisk A/SNovo Nordisk (NVO)
NCT06567041 · 82 participants · Start Aug 7, 2024 · Primary completion Dec 10, 2025
Drug: NNC0519-0130; Placebo · For: Diabetes Mellitus, Type 2; Obesity
Sites: Berlin, Germany
Novo Nordisk A/SNovo Nordisk (NVO)
NCT06513104 · 47 participants · Start Jul 18, 2024 · Primary completion Sep 10, 2025
Drug: NNC0519-0130; Levonorgestrel + Ethinylestradiol and 1 more · For: Diabetes Mellitus, Type 2
Sites: Berlin, Germany
Novo Nordisk A/SNovo Nordisk (NVO)
NCT06642571 · 46 participants · Start Oct 15, 2024 · Primary completion May 17, 2025
Drug: NNC0519-0130 B; NNC0519-0130 C · For: Obesity
Sites: San Antonio, Texas
Novo Nordisk A/SNovo Nordisk (NVO)
NCT06370819 · 36 participants · Start Apr 15, 2024 · Primary completion Nov 27, 2024
Drug: NNC0519-0130 · For: Diabetes Mellitus, Type 2
Sites: Berlin, Germany
Novo Nordisk A/SNovo Nordisk (NVO)
NCT05870670 · 22 participants · Start May 15, 2023 · Primary completion Oct 7, 2023
Drug: NNC0519-0130; Placebo · For: Diabetes Mellitus, Type 2
Sites: Tokyo, Japan
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Chronic Kidney Disease
- CagrilintidePhase 320 trials
Novo Nordisk · Obesity, Overweight, Type 2 Diabetes
- HRS-7535Phase 310 trials
Shandong Suncadia Medicine Co., Ltd. · Type 2 Diabetes, Chronic Kidney Disease, Adults With Heart Failure, Mild Decrease in Ejection Fraction/Preserved Ejection Fraction, and Obesity
- UBT251Phase 310 trials
The United Bio-Technology (Hengqin) Co., Ltd. · Obesity, Obesity &Amp; Overweight, Diabetes Mellitus, Type 2
- ElecoglipronPhase 39 trials
AstraZeneca · Type 2 Diabetes Mellitus, Obesity, Overweight
- ZenagamtidePhase 39 trials
Novo Nordisk · Obesity, Overweight, Type 2 Diabetes
- lorundrostatPhase 35 trials
Mineralys Therapeutics Inc. · Hypertension, Obstructive Sleep Apnea, Chronic Kidney Disease
- VicadrostatBI 690517Phase 35 trials
Boehringer Ingelheim · Heart Failure, Diabetes Mellitus, Type 2, Hypertension
- HRS-1780Phase 33 trials
Shandong Suncadia Medicine Co., Ltd. · Chronic Kidney Disease, Uncontrolled or Resistant Hypertension, Primary Aldosteronism
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Novo Nordisk.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.